Drugs / Sacubitril / Valsartan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04197050 | Feb 2020 → Nov 2022 | connective tissue disorder, myocardial infarction | RenJi Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sacubitril / Valsartan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04197050 ↗ |
| Action | Inhibit | “which inhibits both neprilysin and renin-angiotensin aldosterone system” NCT04197050 ↗ |
| Route | Oral | “Sacubitril / Valsartan Oral Tablet” NCT04197050 ↗ |